|
Thousands of dollars, except per-share amounts and numbers of shares
| 3 |
Goodwill and Other Intangible Assets |
Intangible assets at September 30 consisted of:
| |
2004 |
2003 |
 |
| |
Gross |
|
|
|
|
Gross |
|
|
|
|
| |
Carrying |
|
Accumulated |
|
Carrying |
|
Accumulated |
|
| |
Amount |
|
Amortization |
|
Amount |
|
Amortization |
|
|
| Amortized |
|
|
|
|
|
|
|
|
|
|
|
|
| intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Core and Developed |
|
|
|
|
|
|
|
|
|
|
|
|
| Technology |
$ |
297,342 |
|
$ |
108,801 |
|
$ |
284,432 |
|
$ |
91,194 |
|
| Patents, Trademarks, |
|
|
|
|
|
|
|
|
|
|
|
|
| & Other |
|
307,376 |
|
|
229,047 |
|
|
302,275 |
|
|
214,874 |
|
|
| Total |
$ |
604,718 |
|
$ |
337,848 |
|
$ |
586,707 |
|
$ |
306,068 |
|
|
| Unamortized |
|
|
|
|
|
|
|
|
|
|
|
|
| intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Goodwill(A) |
$ |
473,211 |
|
|
|
|
$ |
445,854 |
|
|
|
|
| Trademarks(B) |
|
15,137 |
|
|
|
|
|
15,137 |
|
|
|
|
|
| Total |
$ |
488,348 |
|
|
|
|
$ |
460,991 |
|
|
|
|
|
| (A) |
Net of accumulated amortization of $176,058 and $172,909 in 2004 and 2003, respectively.
|
| (B) |
Net of accumulated amortization of $6,175 in 2004 and 2003.
|
The change in the carrying amount of goodwill for the year ended September 30, 2004 includes $17,341 related to goodwill recorded in the acquisition of Atto Bioscience, Inc. (see Note 6), as well as foreign currency translation adjustments.
Intangible amortization expense was $31,467, $31,413 and $32,778 in 2004, 2003 and 2002, respectively. The estimated aggregate amortization expense for the fiscal years ending September 30, 2005 to 2009 are as follows: 2005–$31,500; 2006–$28,700; 2007–$28,300; 2008–$27,100; 2009–$25,600.
During the third quarter of fiscal 2003, the Company decided to discontinue the development of certain products and product applications associated with the BD IMAGN instrument platform in the Biosciences segment. As a result, the Company recorded an impairment loss of $26,717 in cost of products sold. This loss included the write down of $25,230 of core and developed technology, $960 of indefinite-lived trademarks, and $527 of licenses. The impairment loss was calculated in accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets.” During 2003, additional asset impairment losses on indefinite-lived trademarks amounted to $1,524 and are included in the loss from discontinued operations.
|
